Background: It is common practice to require patients to stop smoking prior to elective plastic surgery procedures. Scarce research exists describing the impact on mortality and associated societal cost savings with regard to smoking cessation in aesthetic surgery. Objectives: Our objective is to demonstrate that smoking cessation in anticipation for aesthetic surgery significantly reduces mortality and increases societal cost savings. Methods: We performed a systematic literature review of 5 common aesthetic procedures (reduction mammaplasty, breast augmentation, facelift, rhinoplasty, and abdominoplasty) to determine patient smoking rates and subsequent recidivism. Sensitivity analyses estimated life years saved using ranges of recidivism from our literature review and assessed total lifetime savings, including direct and productivity costs, while adjusting for inflation (3%) and interest (5%). One life saved was equated to 45 life years saved. Results: Between May 2008 and May 2013, 7867 patients stopped smoking prior to undergoing aesthetic plastic surgery procedures. Assuming a reported recidivism rate of 68%, smoking cessation prior to aesthetic plastic surgery is associated with 429 lives saved and a total lifetime savings of $524.4 million over the five-year period. Total lives saved ranged from 214 (84% recidivism) to 885 (34% recidivism), and total lifetime cost savings ranged from $262.2 million (84% recidivism) to $1.08 billion (34% recidivism). Conclusions: Presently, smoking cessation before aesthetic surgery significantly saves patient lives with yearly $104.9 million of societal cost savings in the United States. Future reductions in the presently high recidivism rate would lead to additional lives saved and reduced societal costs.
particularly important to aesthetic surgeons and aesthetic surgery patients. 13, 14 A recent study in plastic surgery by Slyke et al reported a smoking cessation or reduction compliance rate of 66.7% (approximately a 34% recidivism rate). 13 Alternatively, the recidivism rate after smoking cessation before spinal fusion was 68% at one year. Smoking recidivism is defined as a return to smoking following cessation for any significant period of time. 14 While data on the connection between smoking and mortality exist, there are scarce data on the effect of smoking on mortality within the context of aesthetic surgery. Current data reveal a high association between mortality and smoking, as smoking leads to a variety of diseases, including cardiovascular disease, lung cancer, and chronic obstructive pulmonary disease. 15, 16 Smoking has also been shown to significantly lower life expectancy by up to 25%. 17 However, the association between mortality and smoking in the context of plastic surgery remains understudied. The complications that result from continued smoking before and after aesthetic surgery can be life threatening and can also lead to heavy financial burdens on our healthcare system.
Given the rising healthcare costs, it is important to continue to explore ways to decrease preventable deaths and costs. The healthcare costs for current smokers can be up to 40% higher than those for nonsmokers. 18, 19 Other studies also show that healthcare costs associated with smoking cessation are most substantial at younger ages, as early cessation leads to fewer health complications over a lifetime period. 20, 21 As most aesthetic procedures are performed on a younger subset of patients, understanding the potential healthcare savings from smoking cessation in this patient population could lead to further insight into the large cost saving potential.
We hypothesize that within 5 common procedures in aesthetic surgery (reduction mammaplasty, breast augmentation, facelift, rhinoplasty, and abdominoplasty), there is the potential for significant mortality reduction and societal cost savings due to smoking cessation in anticipation for aesthetic surgery.
METHODS
We started by performing a systematic literature review using the Preferred Reporting Items for Systematic Reviews and Analyses (PRISMA) guidelines, an evidence-based way of reporting results of systematic reviews. Utilizing the PRISMA flow diagram for conducting systematic reviews found in Figure 1 , we began by identifying articles in 2 main databases as well as through other sources of 5 common aesthetic procedures (reduction mammaplasty, breast augmentation, facelift, rhinoplasty, and abdominoplasty) to determine patient smoking rates and subsequent recidivism. We searched PubMed and Embase for articles with headings including "plastic surgery" and "smoking rate." However, for comprehensive purposes, we used search algorithms that included additional controlled vocabulary terms (ie, MeSH terms in PubMed and Emtree terms in Embase) and keywords to widen the scope of the search and capture all relevant articles (Table 1 ). Two authors (J.A.B. and R.R.) reviewed search results and performed a title and abstract review to evaluate studies for inclusion and exclusion, with disagreements resolved by a third author (A.C.). Studies meeting inclusion criteria were studies looking at smoking rates in aesthetic surgery, particularly in the following 5 surgery subtypes: reduction mammaplasty, breast augmentation, facelift, rhinoplasty, or abdominoplasty. The types of studies that further satisfied our inclusion criteria were randomized controlled trials, prospective analyses, retrospective analyses, and meta-analyses, excluding any standalone posters or abstracts. Additionally, further exclusion criteria were as follows: studies not including 1 of the 5 surgery subtypes or papers with no clear discussion on smoking rates. We also excluded papers not published in American or European journals.
A total of 170 articles were reviewed. For studies meeting inclusion criteria, we reviewed each study to determine if the specifics of smoking rates were discussed in the Introduction, Methodology, Results, or Discussion sections. Only 4 articles satisfied all inclusion and exclusion criteria. These 4 papers provided us with epidemiological data, which included cosmetic patients with a hospital admission from May 2008 to May 2013 undergoing a reduction mammaplasty, breast augmentation, facelift, rhinoplasty, or abdominoplasty (Table 2) . [9] [10] [11] [12] A sensitivity analysis examining lives saved and total lifetime savings was conducted using this range of recidivism rates. Life years saved were defined as the difference between the average smoker's life expectancy as compared to that of the average nonsmoker 15 and a single life was defined as equivalent to 45 years, or the difference between an average nonsmoker's life expectancy and the average age at presentation for plastic surgery. This assumption reflected the amount of life years saved from smoking-related morbidity. Therefore, total lives saved equaled total life years saved divided by 45 years. Total lifetime savings were found to be $1363 per person per year in US dollars from a Danish nationwide retrospective study. This amount reflects both direct (healthcare associated) and productivity costs from smoking-related morbidity (retirement before age 69 and absent days). 21 These values were then adjusted for both inflation (3%) and interest (5%) in our sensitivity analysis. The guiding principles of the Declaration of Helsinki were adhered to in this research design.
RESULTS
Between May 2008 and May 2013, 94,820 patients underwent reduction mammaplasty, breast augmentation, facelift, rhinoplasty, or abdominoplasty. A total of 7867 patients stopped smoking prior to undergoing aesthetic plastic surgery procedures (Table 2) .
While results of the literature review showed no clear recidivism rates defined in our population, we chose recidivism rates of 84%, 68%, and 34% for our sensitivity analysis. These were selected, as Slyke et al reported a smoking cessation or reduction compliance rate of 66.7% (approximately a 34% recidivism rate) in aesthetic surgery patients, 13 and the recidivism rate after smoking cessation before spinal fusion was 68%. 14 The abstinence rate of the 68% group was 32%. A more conservative abstinence rate of 16% was chosen by the authors, thus providing a recidivism rate of 84%.
Assuming a reported recidivism rate of 68%, smoking cessation prior to aesthetic plastic surgery is associated with 429 lives saved and a total lifetime savings of $524.4 million over the 5-year period. Total lives saved ranged from 214 (84% recidivism) to 885 (34% recidivism), and total lifetime cost savings ranged from $262.2 million (84% recidivism) to $1.08 billion (34% recidivism) (Tables 3 and 4) .
DISCUSSION
The morbidity of smoking in plastic surgery patients has been well documented [1] [2] [3] [4] ; however, this is the first study, to the best of our knowledge, to evaluate the impact of smoking cessation and subsequent recidivism on mortality and Embase ("plastic surgery"/de OR "aesthetic surgery" OR "face lift" OR "rhinoplasty" OR "abdominoplasty" OR "breast augmentation" OR "reduction mammoplasty") AND ("smoking rate" OR "nicotine" OR "tobacco") Total patients reflected the number of patients who underwent each studied procedure during the studied time period. [9] [10] [11] [12] the societal financial implications of such an intervention.
Smoking recidivism is directly related to mortality, as these patients who return to smoking after a period of cessation are still at risk for smoking-related diseases and death. Despite the limited data on smoking cessation and cost savings within the aesthetic surgery patient population, our study results align well with prior studies in other medical fields, which have established that smoking yields drastic costs to society. 3 Such studies, however, have not addressed smoking cessation outcomes with regard to mortality in the aesthetic plastic surgery population, which is relatively young and motivated to maximize surgical outcomes. 22, 23 This provides an excellent opportunity for plastic surgeons practicing aesthetic surgery to make a meaningful impact on society with regard to improvements on mortality and societal cost savings by continuing to improve their efforts for smoking cessation. However, the key players in smoking cessation in aesthetic surgery involve the patient, the surgeon, and the existence of a system of patient support. Presently, even the optimistic recidivism rate of 34% is too high, given that the very outcome of permanent smoking cessation will likely save the patient's life. Many surgeons would concur that the action of successfully stopping a patient from smoking permanently is a far greater long-term achievement as a healthcare provider than any successful aesthetic outcome (although smoking cessation also helps in this as well). However, while the drive to counsel patients in stopping smoking during the initial aesthetic consultation is present, there is very little with regard to a system of support that is provided for the patient and the consulting plastic surgeon to lean upon, especially in the private practice setting. 13 Smoking cessation literature notes that specialized smoking healthcare providers who can not only counsel a patient on smoking but also provide other forms of treatment such as medications and hypnosis decrease recidivism rates. 1 Without this system, it is challenging to further reduce recidivism rates. Our results with the sensitivity analysis provide ample evidence to show that society gains from reducing smoking permanently. A recidivism rate of 34% compared to 84% has a savings of approximately $738 million to society. This is aside from actual human lives saved, but from a governmental budget standpoint, it would justify assistance to those interested plastic surgeons contributing to societal smoking cessation. Such governmental assistance could come in several ways. For example, governmental expenditure could create counseling hotlines that could be referred to by smaller plastic surgery practices that identify smoking patients interested in smoking cessation. 24 Additionally, smoking cessation and recidivism rates could be used as an incentive quality metric for participating plastic surgeons who, after achieving a stated recidivism goal, could obtain tax incentives as positive reinforcements for their efforts in smoking cessation. Of course, tracking the patients would be a challenge but for these programs, a pilot program would need to be established to fix the possible errors for a future, larger program. However, the results shown in this study can be used to justify the establishment of such programs with governmental funding on a state or federal level, which can then assist smaller private practices with tools that are presently needed to bring down the recidivism smoking rate. Nevertheless, incentive programs have empirically shown to change physician behavior, and the possible cost savings demonstrated in this study can help justify setting up governmental incentive programs to assist motivated plastic surgeons to further improve on recidivism rates in the aesthetic surgical population. 25 As with any study, there are several limitations to this study that should be acknowledged. The first limitation was the reliance of the study on data from other published studies, which could result in confirmation bias. The validity of our analysis depends on unbiased estimates of epidemiological and economic parameters. To address this, the authors underwent a comprehensive systematic literature review to identify all reported aesthetic surgery patients who stopped smoking prior to their procedure. Second, it was difficult for the authors to properly identify an appropriate recidivism rate for the study's patient population, given the current lack of recidivism data in this subset of patients. To account for this, our calculations included a range of recidivism rates from previously published papers, and we performed a sensitivity analysis in the hopes of capturing the true recidivism rate for our patient population. 13, 14 Furthermore, there is obvious room for patient deceit when reporting smoking status, making it difficult to identify an accurate cessation and recidivism rate. A study published by Coon et al showed that about 4.1% of their 415 patients denied current tobaccos use despite positive urine cotinine samples. This study also found that patients with smoking Life years saved were defined as the difference between the average smoker's life expectancy as compared to that of the average nonsmoker. [9] [10] [11] [12] history were more deceitful than patients who have never smoked (P < 0.001), illustrating the difficulty in accurately detecting tobaccos use. 23 Moreover, the patient population is extrapolated from the CosmetAssure database, which has many limitations of its own, including no details regarding the number of cigarettes consumed per day, pack year history, smoking status leading up to or immediately after surgery, or the type of cigarettes. Therefore, we were forced to make several assumptions throughout our data analysis. We assumed that all patients who were smokers stopped smoking prior to surgery, and based upon our sensitivity analysis, a certain proportion of these patients returned to smoking. Given the retrospective nature of this study, accounting for this limitation was difficult. A prospective study utilizing a systematic way for definitively detecting smoking preoperatively and postoperatively is needed to identify a more accurate recidivism rate for the aesthetic patient population. An additional limitation involves our societal cost-analysis using $1363 per person per year in US dollars. While we attempted to account for inflation and interest in our calculations, this number given its European roots is likely to be underestimating the true societal cost. Traditionally, in cost-effectiveness and cost-utility analysis literature, the value per quality adjusted life year has been lower for Europeans than Americans, demonstrated by a lower willingness to pay in the European literature compared to the US literature. [26] [27] [28] [29] Thus, our estimates for societal costs, if anything, may be underinflated, which would only strengthen our argument that true societal costs saved from improved recidivism rates can financially justify the creation of new governmental assistance programs that can assist plastic surgeons further decrease recidivism rates. Even while taking into account these limitations, there are several important implications of this research. There is no doubt that there is a unanimous understanding that smoking cessation prior to aesthetic surgery is important and should be routinely practiced. In spite of this need, the large study by Rohrich et al including 955 North American plastic surgeons demonstrated that 60% (P < 0.01) of plastic surgeons routinely performed less than optimal procedures on patients who smoke, and only about 16% (P < 0.01) would perform a nicotine test if they suspected noncompliance. 30 This is in line with surgeons who chose to operate upon patients who are current smokers after embarking upon a risk-benefit discussion preoperatively. 31 There also remains debate surrounding the appropriate preoperative smoking cessation duration time period among surgeons. 1, 7, 8, 32 Properly educating surgeons and their patients on the wide array of smoking cessation methods, particularly pharmacotherapy, can help yield lifelong abstinence, but a system for such education is needed. 33 Not to mention, with the advent of hospital quality measures and the focus on outcome-based medicine, such an intervention will also be beneficial to surgeons and the hospitals in which they are employed.
CONCLUSIONS
In conclusion, in assuming a reported recidivism rate of 68%, we identified smoking cessation prior to aesthetic plastic surgery is associated with 429 lives saved and a total lifetime savings of $524.4 million over the 5-year period. We hope that this study will be used to highlight the importance of smoking cessation prior to aesthetic surgery by estimating lives saved and societal cost savings, so that future assistance programs can be established to further reduce the presently high recidivism rate, which ultimately benefits society, the surgeon, and the patient.
We feel that the aesthetic surgeon can play an important role in patient smoking cessation. It takes time to enact change, and the preoperative smoking cessation counseling of the aesthetic plastic surgeon can play a major role in bringing about lasting change. We believe that better surgical outcomes and reduced lifetime mortality from smoking will motivate the aesthetic surgery patient to cease smoking if presented with adequate resources.
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